Timessquare Capital Management Lowered K2m Group Holdings (KTWO) Position By $4.33 Million; 4 Analysts Bullish Vanda Pharmaceuticals Inc. (VNDA)

K2M Group Holdings, Inc. (NASDAQ:KTWO) Logo

Among 5 analysts covering Vanda Pharmaceuticals (NASDAQ:VNDA), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. Vanda Pharmaceuticals had 5 analyst reports since August 23, 2018 according to SRatingsIntel. The rating was maintained by Citigroup on Tuesday, October 16 with “Buy”. The stock has “Outperform” rating by Oppenheimer on Friday, September 21. See Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) latest ratings:

08/11/2018 Broker: Jefferies Rating: Buy New Target: $26 Initiates Coverage On
16/10/2018 Broker: Citigroup Old Rating: Buy New Rating: Buy Old Target: $27 New Target: $31 Maintain
21/09/2018 Broker: Oppenheimer Old Rating: Outperform New Rating: Outperform Old Target: $27 New Target: $29 Maintain
14/09/2018 Broker: Stifel Nicolaus Rating: Buy New Target: $30 Initiates Coverage On
23/08/2018 Broker: Cantor Fitzgerald Rating: Neutral New Target: $26 Initiates Coverage On

Timessquare Capital Management Llc decreased K2m Group Holdings Inc (KTWO) stake by 7.49% reported in 2018Q2 SEC filing. Timessquare Capital Management Llc sold 196,700 shares as K2m Group Holdings Inc (KTWO)’s stock rose 18.42%. The Timessquare Capital Management Llc holds 2.43M shares with $54.66 million value, down from 2.63 million last quarter. K2m Group Holdings Inc now has $1.20 billion valuation. It closed at $27.5 lastly. It is down 17.76% since December 8, 2017 and is uptrending. It has outperformed by 2.14% the S&P500. Some Historical KTWO News: 21/04/2018 – DJ K2M Group Holdings Inc, Inst Holders, 1Q 2018 (KTWO); 16/05/2018 – K2M LAUNCHES 3D-PRINTED EXPANDABLE INTERBODY MOJAVE™ PL 3D; 09/05/2018 – Bellevue Group AG Buys New 1.5% Position in K2M; 16/05/2018 – K2M Announces US Launch of First-to-Market 3D-Printed Expandable lnterbody MOJAVE™ PL 3D Expandable Featuring Lamellar 3D Titanium Technology™; 01/05/2018 – K2M Group Holdings: Updating Fiscal Yr 2018 Expectations for Rev, Net Loss, Adjusted EBITDA; 29/03/2018 – K2M Names Lane Major Chief Operating Officer; 29/03/2018 – K2M NAMES LANE MAJOR COO; 01/05/2018 – K2M Group Holdings 1Q Rev $67.9M; 01/05/2018 – K2M Group Holdings Sees Growth in U.S. Business 10%-11% Vs. Year Ago; 27/04/2018 – Consolidated Research: 2018 Summary Expectations for Kinsale Capital Group, K2M Group, PriceSmart, Arlington Asset Investment,

Timessquare Capital Management Llc increased Encompass Health Corporat stake by 327,950 shares to 839,872 valued at $56.88 million in 2018Q2. It also upped Acceleron Pharma Inc (NASDAQ:XLRN) stake by 44,650 shares and now owns 376,655 shares. Exela Technologies Inc was raised too.

Among 4 analysts covering K2M Group Holdings (NASDAQ:KTWO), 0 have Buy rating, 0 Sell and 4 Hold. Therefore 0 are positive. K2M Group Holdings had 4 analyst reports since August 31, 2018 according to SRatingsIntel. The firm has “Sector Perform” rating by RBC Capital Markets given on Monday, September 24. The stock of K2M Group Holdings, Inc. (NASDAQ:KTWO) has “Perform” rating given on Friday, August 31 by Oppenheimer. The rating was downgraded by Cowen & Co to “Market Perform” on Wednesday, September 5. The stock of K2M Group Holdings, Inc. (NASDAQ:KTWO) earned “Neutral” rating by Cantor Fitzgerald on Tuesday, September 4.

More notable recent K2M Group Holdings, Inc. (NASDAQ:KTWO) news were published by: Nasdaq.com which released: “K2M Group (KTWO) Reports Q3 Loss, Lags Revenue Estimates – Nasdaq” on November 12, 2018, also Globenewswire.com with their article: “K2M Group Holdings, Inc. Stockholders Approve Acquisition by Stryker – GlobeNewswire” published on November 07, 2018, Nasdaq.com published: “Factors of Influence in 2018, Key Indicators and Opportunity within McDermott International, SunPower, EastGroup Properties, K2M Group, Lumber Liquidators, and IDEX — New Research Emphasizes Economic Growth – Nasdaq” on November 05, 2018. More interesting news about K2M Group Holdings, Inc. (NASDAQ:KTWO) were released by: Seekingalpha.com and their article: “K2M Gets A Boost From A Stronger Spine Market – Seeking Alpha” published on August 07, 2018 as well as Globenewswire.com‘s news article titled: “K2M Group Holdings, Inc. Announces Definitive Agreement To Be Acquired by Stryker Corporation – GlobeNewswire” with publication date: August 30, 2018.

More notable recent Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) news were published by: Nasdaq.com which released: “Noteworthy Monday Option Activity: GM, AMWD, VNDA – Nasdaq” on December 03, 2018, also Nasdaq.com with their article: “Health Care Sector Update for 12/03/2018: TSRO, GSK, VNDA, GBT, JNJ, PFE, ABT, MRK, AMGN – Nasdaq” published on December 03, 2018, Seekingalpha.com published: “Healthcare and Industrial goods dominate midday movers – Seeking Alpha” on December 03, 2018. More interesting news about Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) were released by: Nasdaq.com and their article: “Zacks.com highlights: Vericel, Mitek, Vanda Pharmaceuticals, Mosaic and Spirit Airlines – Nasdaq” published on November 29, 2018 as well as Benzinga.com‘s news article titled: “Benzinga’s Top Upgrades, Downgrades For December 4, 2018 – Benzinga” with publication date: December 04, 2018.

The stock decreased 6.19% or $1.82 during the last trading session, reaching $27.6. About 653,288 shares traded. Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) has risen 6.96% since December 8, 2017 and is uptrending. It has underperformed by 8.66% the S&P500. Some Historical VNDA News: 09/04/2018 – Vanda Pharma Closes Below 200-Day Moving Average: Technicals; 13/04/2018 – VANDA PHARMACEUTICALS INC – ‘610 PATENT IS SET TO EXPIRE NOVEMBER 2, 2027; 15/05/2018 – Invesco Buys New 2.5% Position in Vanda Pharma; 20/04/2018 – MARSHALLS PLC MSLH.L – ANNOUNCES ITS INTENTION TO APPOINT VANDA MURRAY OBE TO BOARD AS NON-EXECUTIVE DIRECTOR AND CHAIR OF BOARD; 02/05/2018 – Vanda Pharmaceuticals: Reiterates Prior 2018 Fincl Guidance; 29/03/2018 – Delaware Healthcare Adds Smith & Nephew, Exits Vanda Pharma; 02/05/2018 – Vanda Pharmaceuticals 1Q Adj EPS 14c; 15/03/2018 – Vanda Pharmaceuticals Inc. Prices Public Offering of Common Stkat $17/Share; 10/04/2018 – Vanda Pharma at Deutsche Bank Health Care Conference May 9; 20/05/2018 – Vanda Insights Doesn’t See U.S. Oil Sanctions Against Venezuela (Video)

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system disorders. The company has market cap of $1.45 billion. The companyÂ’s marketed products include HETLIOZ , a product for the treatment of non-24-hour sleep-wake disorder; and Fanapt (iloperidone), a product for the treatment of schizophrenia. It has a 108.66 P/E ratio. The Company’s clinical development products include Tradipitant (VLY-686), a small molecule neurokinin-1 receptor antagonist that is under the clinical development for the treatment of chronic pruritus in atopic dermatitis and gastroparesis; Trichostatin A, a small molecule histone deacetylase inhibitor, which is in development for the treatment of hematologic malignancies; and AQW051, a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist.

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.